The aging process known as senescence is a mechanism involved in the failure of CAR T-cell therapy, according to a study by researchers at the Mayo Clinic.
Specific sequences of chemotherapy, targeted therapy, and immunotherapy yielded significantly different results, according to a study that utilized simulation models and real-world data to predict outcomes under different sequencing scenarios.
Cancer deaths linked to obesity have tripled in the United States over the past two decades, according to a study presented at ENDO 2025 in July.
Xtandi (enzalutamide) plus ADT significantly slows disease progression vs darolutamide plus ADT in patients with mHSPC, according to a matching-adjusted indirect comparison analysis published in Future Oncology.
A mother’s mitochondria determines if lactation is protective or not against breast cancer—and points to a possible intervention to increase the benefit to more women, according to a pre-clinical study conducted by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Spatial mapping experiments reveal that topologically associating domains in individual cells tend to take a globular shape, according to a study conducted by scientists at Sanford Burnham Prebys and colleagues in Hong Kong.
A multi-institutional study focused on how subtle challenges to women’s authority accumulate over time, leading to increased rates of burnout, discouraging women from staying in male-dominated careers.
Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to research led by researchers at Keck Medicine of USC.
Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a cohort study from Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.
